We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
COO posted Q4 EPS and revenue beat, driven by operational gains and stronger product demand.
MyDay contract wins and solid MiSight growth supported revenue increases across CVI.
CSI saw broader gains as PARAGARD rebounded and fertility benefited from genomics strength.
The Cooper Companies, Inc. (COO - Free Report) delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.15, which improved 11% year over year. The figure beat the Zacks Consensus Estimate of $1.11 by 3.6%. Operational improvements drove the bottom-line growth.
GAAP EPS for the quarter was 43 cents, down 27% year over year.
COO’s Revenues in Detail
Revenues totaled $1.065 billion, up 5% year over year on a reported basis and up 3% organically. The figure beat the Zacks Consensus Estimate by 0.5%.
The quarterly revenues were up 3% year over year at constant exchange rate (CER).
The better-than-expected top-line performance was mainly due to momentum with MyDay contract wins and strong MiSight sales.
Following strong results, shares of COO were up almost 13% on Dec. 4. The company’s shares have lost 16.2% so far this year against the industry’s gain of 10.7%. The S&P 500 Index was up 19% during the same period.
Image Source: Zacks Investment Research
Cooper Companies’ Segmental Details
COO conducts its business via two reportable segments — CooperVision (“CVI”) and CooperSurgical (“CSI”).
For the fourth quarter of fiscal 2025, the CVI segment’s revenues totaled $709.6 million, up 5% year over year on a reported basis and 3% at CER as well as organically. This figure compares to our segmental projection of $709 million.
Growth was driven by improved global availability of MyDay, partially offset by market softness in China and certain areas in the EMEA. MyDay lenses continued its double-digit growth rate. Biofinity and Avaira grew 2%, while MiSight delivered strong growth of 37%. However, weakness in Clariti lens sales continued in the fiscal fourth quarter as the global contact lens market continues to trend toward premium offerings, which included MyDay offerings.
Category-wise, CVI derives revenues from Toric and multifocal, Sphere and others.
In the fiscal fourth quarter, Toric and multifocal revenues totaled $344.6 million, up 7% year over year on a reported basis, and up 5% organically as well as at CER. This figure compares to our projection of $344.2 million.
Sphere and other revenues totaled $365 million, up 3% year over year on a reported basis and up 2% at CER as well as organically. This figure compares to our projection of $364.9 million.
Geographically, CVI derives revenues from the Americas, Europe and the Asia Pacific.
Americas’ revenues totaled $285.1 million, up 5% year over year on a reported basis as well as at CER and organically. The figure compares to our projection of $290.5 million.
EMEA revenues amounted to $277.1 million, up 8% year over year on a reported basis and up 3% at CER and organically. This figure compares to our projection of $272.8 million.
Asia Pacific revenues in the fiscal fourth quarter totaled $147.4 million, down 1% year over year reportedly and flat organically and at CER. Strong MyDay sales growth was offset primarily by a 28% decline in China, driven by continued weakness in low-margin e-commerce channels. This figure compares to our projection of $145.7 million.
The CSI segment’s revenues totaled $355.6 million, which moved up 4% on a reported basis as well as at CER and organically. This figure compares to our projection of $350.9 million.
Category-wise, CSI derives revenues from Office and surgical, and Fertility. In the fiscal fourth quarter, Office and surgical revenues totaled $214.6 million, up 6% on a reported basis and at CER and organically. This figure compares to our projection of $207.5 million. PARAGARD sales returned to growth following a decline in the fiscal third quarter, driven by strong demand for the recently-launched single-hand inserter upgrade. Medical devices grew 3%, led by double-digit growth in the labor and delivery portfolio and a 35% increase in the obp Surgical line of innovative single-use lighted cordless surgical retractors.
Fertility revenues in the fiscal fourth quarter amounted to $141 million, up 1% on a reported basis as well as organically and at CER year over year, supported by genomics and market share gains in the EMEA, partially offset by softness in the United States. This figure compares to our projection of $143.4 million.
COO’s Margin Trend
In the quarter under review, Cooper Companies’ adjusted gross profit rose 3.4% to $704.7 million. However, the adjusted gross margin contracted almost 70 basis points (bps) to 66%, hurt by an unfavorable product mix and tariff headwinds. We had projected 68.5% of gross margin for the fiscal fourth quarter.
Selling, general and administrative expenses rose 7.1% to $419.2 million. Research and development expenses increased 9.8% to $41.4 million. Adjusted operating costs totaled $416.7 million, reflecting a 0.4% decrease from the prior-year quarter’s level.
Adjusted operating profit totaled $288 million, reflecting a 9.4% increase from the year-earlier quarter’s level. The adjusted operating margin in the fiscal fourth quarter expanded 110 bps to 27%.
Cooper Companies’ Financial Position
COO exited the fourth quarter of fiscal 2025 with cash and cash equivalents of $110.6 million compared with $124.9 million at the end of the fiscal third quarter.
Total debt at the end of the fiscal fourth quarter was $2.51 billion compared with $2.48 billion at the end of the fiscal third quarter.
COO’s Guidance
Cooper Companies has provided its outlook for fiscal 2026.
The company expects revenues in the range of $4,299-$4,338 million, suggesting an organic improvement of 3-4% from the prior-year figure. The Zacks Consensus Estimate is pegged at $4.31 billion.
COO expects the CVI segment’s revenues in the range of $2,900-$2,925 million, suggesting an organic improvement of 4.5-5.5% from the year-earlier registered figure.
The company anticipates the CSI segment’s revenues in the band of $1,399-$1,413 million, indicating an organic improvement of 4-5% from the year-earlier figure.
For the entire fiscal year, adjusted EPS is expected in the $4.45-$4.60 range. The Zacks Consensus Estimate is pegged at $4.38.
The Cooper Companies, Inc. Price, Consensus and EPS Surprise
The Cooper Companies’ fiscal fourth-quarter results highlight solid performance, with earnings and sales beating estimates. Moreover, better-than-expected guidance for fiscal 2026 looks promising.
Cooper Companies enters fiscal 2026 with multiple growth catalysts across both CVI and CSI segments. CVI’s momentum is anchored in the global rollout of the MyDay portfolio, expanded private-label wins across the United States, Europe and the Asia-Pacific, and a slate of new 2026 launches, including MyDay, MiSight and MyDay toric multifocal. The company also expects MiSight to deliver another 20-25% growth, supported by its launches in Europe and Japan. Meanwhile, CSI benefits from new fertility genomics tests, strengthening demand for Witness lab-tracking technology and PARAGARD’s upgraded single-hand inserter, all of which are drawing increased customer interest.
Cooper’s aggressive reorganization and integration initiatives, enabled by AI-driven operational efficiencies, are set to unlock roughly $50 million in annual savings, improving operating margins and supporting robust cash-flow generation. Additional tailwinds include contract wins, easing supply constraints and a more normalized CapEx profile beginning in 2027.
However, 2026 is not without persistent challenges. COO continues to face gross margin pressure from tariffs and product mix, particularly as daily silicone hydrogel volumes rise. Regional risks —most notably ongoing weakness in China’s e-commerce channel and conservative fertility spending, especially in the Asia-Pacific — are also expected to weigh on early-year performance.
COO’s Zacks Rank and Stocks to Consider
COO currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Sight Sciences (SGHT - Free Report) .
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 earnings per share (EPS) of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Sight Sciences, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted loss of 16 cents per share, which surpassed the Zacks Consensus Estimate by 38.46%. Revenues of $20 million outperformed the Zacks Consensus Estimate by 16%.
SGHT’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 8.73%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises
Key Takeaways
The Cooper Companies, Inc. (COO - Free Report) delivered fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.15, which improved 11% year over year. The figure beat the Zacks Consensus Estimate of $1.11 by 3.6%. Operational improvements drove the bottom-line growth.
GAAP EPS for the quarter was 43 cents, down 27% year over year.
COO’s Revenues in Detail
Revenues totaled $1.065 billion, up 5% year over year on a reported basis and up 3% organically. The figure beat the Zacks Consensus Estimate by 0.5%.
The quarterly revenues were up 3% year over year at constant exchange rate (CER).
The better-than-expected top-line performance was mainly due to momentum with MyDay contract wins and strong MiSight sales.
Following strong results, shares of COO were up almost 13% on Dec. 4. The company’s shares have lost 16.2% so far this year against the industry’s gain of 10.7%. The S&P 500 Index was up 19% during the same period.
Image Source: Zacks Investment Research
Cooper Companies’ Segmental Details
COO conducts its business via two reportable segments — CooperVision (“CVI”) and CooperSurgical (“CSI”).
For the fourth quarter of fiscal 2025, the CVI segment’s revenues totaled $709.6 million, up 5% year over year on a reported basis and 3% at CER as well as organically. This figure compares to our segmental projection of $709 million.
Growth was driven by improved global availability of MyDay, partially offset by market softness in China and certain areas in the EMEA. MyDay lenses continued its double-digit growth rate. Biofinity and Avaira grew 2%, while MiSight delivered strong growth of 37%. However, weakness in Clariti lens sales continued in the fiscal fourth quarter as the global contact lens market continues to trend toward premium offerings, which included MyDay offerings.
Category-wise, CVI derives revenues from Toric and multifocal, Sphere and others.
In the fiscal fourth quarter, Toric and multifocal revenues totaled $344.6 million, up 7% year over year on a reported basis, and up 5% organically as well as at CER. This figure compares to our projection of $344.2 million.
Sphere and other revenues totaled $365 million, up 3% year over year on a reported basis and up 2% at CER as well as organically. This figure compares to our projection of $364.9 million.
Geographically, CVI derives revenues from the Americas, Europe and the Asia Pacific.
Americas’ revenues totaled $285.1 million, up 5% year over year on a reported basis as well as at CER and organically. The figure compares to our projection of $290.5 million.
EMEA revenues amounted to $277.1 million, up 8% year over year on a reported basis and up 3% at CER and organically. This figure compares to our projection of $272.8 million.
Asia Pacific revenues in the fiscal fourth quarter totaled $147.4 million, down 1% year over year reportedly and flat organically and at CER. Strong MyDay sales growth was offset primarily by a 28% decline in China, driven by continued weakness in low-margin e-commerce channels. This figure compares to our projection of $145.7 million.
The CSI segment’s revenues totaled $355.6 million, which moved up 4% on a reported basis as well as at CER and organically. This figure compares to our projection of $350.9 million.
Category-wise, CSI derives revenues from Office and surgical, and Fertility.
In the fiscal fourth quarter, Office and surgical revenues totaled $214.6 million, up 6% on a reported basis and at CER and organically. This figure compares to our projection of $207.5 million. PARAGARD sales returned to growth following a decline in the fiscal third quarter, driven by strong demand for the recently-launched single-hand inserter upgrade. Medical devices grew 3%, led by double-digit growth in the labor and delivery portfolio and a 35% increase in the obp Surgical line of innovative single-use lighted cordless surgical retractors.
Fertility revenues in the fiscal fourth quarter amounted to $141 million, up 1% on a reported basis as well as organically and at CER year over year, supported by genomics and market share gains in the EMEA, partially offset by softness in the United States. This figure compares to our projection of $143.4 million.
COO’s Margin Trend
In the quarter under review, Cooper Companies’ adjusted gross profit rose 3.4% to $704.7 million. However, the adjusted gross margin contracted almost 70 basis points (bps) to 66%, hurt by an unfavorable product mix and tariff headwinds. We had projected 68.5% of gross margin for the fiscal fourth quarter.
Selling, general and administrative expenses rose 7.1% to $419.2 million. Research and development expenses increased 9.8% to $41.4 million. Adjusted operating costs totaled $416.7 million, reflecting a 0.4% decrease from the prior-year quarter’s level.
Adjusted operating profit totaled $288 million, reflecting a 9.4% increase from the year-earlier quarter’s level. The adjusted operating margin in the fiscal fourth quarter expanded 110 bps to 27%.
Cooper Companies’ Financial Position
COO exited the fourth quarter of fiscal 2025 with cash and cash equivalents of $110.6 million compared with $124.9 million at the end of the fiscal third quarter.
Total debt at the end of the fiscal fourth quarter was $2.51 billion compared with $2.48 billion at the end of the fiscal third quarter.
COO’s Guidance
Cooper Companies has provided its outlook for fiscal 2026.
The company expects revenues in the range of $4,299-$4,338 million, suggesting an organic improvement of 3-4% from the prior-year figure. The Zacks Consensus Estimate is pegged at $4.31 billion.
COO expects the CVI segment’s revenues in the range of $2,900-$2,925 million, suggesting an organic improvement of 4.5-5.5% from the year-earlier registered figure.
The company anticipates the CSI segment’s revenues in the band of $1,399-$1,413 million, indicating an organic improvement of 4-5% from the year-earlier figure.
For the entire fiscal year, adjusted EPS is expected in the $4.45-$4.60 range. The Zacks Consensus Estimate is pegged at $4.38.
The Cooper Companies, Inc. Price, Consensus and EPS Surprise
The Cooper Companies, Inc. price-consensus-eps-surprise-chart | The Cooper Companies, Inc. Quote
Our Take
The Cooper Companies’ fiscal fourth-quarter results highlight solid performance, with earnings and sales beating estimates. Moreover, better-than-expected guidance for fiscal 2026 looks promising.
Cooper Companies enters fiscal 2026 with multiple growth catalysts across both CVI and CSI segments. CVI’s momentum is anchored in the global rollout of the MyDay portfolio, expanded private-label wins across the United States, Europe and the Asia-Pacific, and a slate of new 2026 launches, including MyDay, MiSight and MyDay toric multifocal. The company also expects MiSight to deliver another 20-25% growth, supported by its launches in Europe and Japan. Meanwhile, CSI benefits from new fertility genomics tests, strengthening demand for Witness lab-tracking technology and PARAGARD’s upgraded single-hand inserter, all of which are drawing increased customer interest.
Cooper’s aggressive reorganization and integration initiatives, enabled by AI-driven operational efficiencies, are set to unlock roughly $50 million in annual savings, improving operating margins and supporting robust cash-flow generation. Additional tailwinds include contract wins, easing supply constraints and a more normalized CapEx profile beginning in 2027.
However, 2026 is not without persistent challenges. COO continues to face gross margin pressure from tariffs and product mix, particularly as daily silicone hydrogel volumes rise. Regional risks —most notably ongoing weakness in China’s e-commerce channel and conservative fertility spending, especially in the Asia-Pacific — are also expected to weigh on early-year performance.
COO’s Zacks Rank and Stocks to Consider
COO currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Sight Sciences (SGHT - Free Report) .
Medpace, currently carrying a Zacks Rank #2 (Buy), reported a third-quarter 2025 earnings per share (EPS) of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Sight Sciences, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted loss of 16 cents per share, which surpassed the Zacks Consensus Estimate by 38.46%. Revenues of $20 million outperformed the Zacks Consensus Estimate by 16%.
SGHT’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 8.73%.